Immunotherapy plus chemo for gastroesophageal junction cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug (pucotenlimab), which helps your immune system fight cancer, combined with chemotherapy, given before and after surgery for gastroesophageal junction cancer. The goal is to see if this combination can shrink the tumor and improve outcomes for patients with this type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of cancer called gastroesophageal junction cancer that is locally advanced but can be removed with surgery.
- You must not have had any prior cancer treatment for this disease (like chemotherapy, radiation, or surgery).
- You must be in fairly good health, able to care for yourself, and expected to live at least 3 more months.
- Your vital organs (like liver, kidneys, and heart) must be working well enough, based on standard blood tests and heart check.
- You must agree to use birth control if there is any chance of pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs before surgery for people with resectable gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to shrink gastroesophageal junction cancer before surgery. It aims to make the tumor removable and improve outcomes.
This trial combines an experimental immunotherapy drug with standard chemotherapy before and after surgery for patients with a specific type of stomach-esophagus cancer. The goal is to see if this combination improves outcomes, including shrinking the tumor to make surgery more effective.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
This Phase 2 study tests giving immunotherapy together with chemotherapy before surgery for certain “locally advanced” cancers at the esophagus-stomach junction. It may help shrink the tumor and improve outcomes by treating the cancer earlier with both immune and chemotherapy approaches.
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
Hear when a new Gastroesophageal Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.